Serum alpha-fetoprotein in 184 ugandan patients with hepatocellular carcinoma.Clinical, laboratory, and histopathologic correlations

Vogel, Charles L.; Primack, Aron; McIntire, K. Robert; Carbone, Paul P.; Anthony, P. P.

doi:10.1002/1097-0142(197404)33:4<959::aid-cncr2820330410>3.0.co;2-v

Cited by 38 publications

(8 citation statements)

References 20 publications

(1 reference statement)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The correlation between AFP level and grade of tumor cell differentiation has been reported incoherently. Some reports showed that the presence of AFP tended to correlate with poorly differentiated HCC or high grade HCC,28, 30, 31 whereas other reports revealed no correlation between AFP level and tumor grade 32, 33. Conversely, two reports stated that patients with both Grade 1 and Grade 4 HCC were associated with lower serum AFP levels 34, 35.…”

Section: Discussionmentioning

confidence: 99%

Paraneoplastic syndromes in patients with hepatocellular carcinoma in Taiwan

Luo

Hwang

et al. 1999

Cancer

View full text Add to dashboard Cite

BACKGROUND Hepatocellular carcinoma (HCC) is the most common malignancy in Taiwan. Some patients may manifest paraneoplastic syndromes during the clinical course of the disease. In this study, the authors evaluated the clinical significance of these paraneoplastic syndromes, compared the prevalence of these syndromes between cases of hepatitis B virus (HBV)–related and hepatitis C virus (HCV)–related HCC, and estimated significant predictors associated with the syndromes. METHODS Clinical data on 1197 HCC patients, including age, gender, Child–Pugh score, survival time, laboratory data (including liver biochemistry, hepatitis markers, and serum α‐fetoprotein [AFP]), and tumor features (including tumor size, portal vein thrombosis, and histologic pictures), were retrospectively reviewed. RESULTS A total of 232 of 1197 patients (19.4%) had paraneoplastic syndromes. HCC patients with paraneoplastic syndromes had significantly higher serum AFP; higher rates of initial main portal vein thrombosis, metastasis, and bilobal tumor involvement; larger tumor volume; and shorter survival than those without these syndromes. Patients with HBV‐related HCC had a significantly higher prevalence of paraneoplastic syndromes than patients with HCV‐related HCC (20.1% vs. 11.2%, P = 0.005). In a stepwise multivariate logistic regression analysis, AFP >50,000 ng/mL and tumor volume >30% were significant predictive variables associated with the presence of paraneoplastic syndromes in HCC patients. CONCLUSIONS HCC patients with paraneoplastic syndromes usually had higher levels of serum AFP and larger tumor volumes than those without. Patients with HBV‐related HCC had a significantly higher prevalence of paraneoplastic syndromes than those with HCV‐related HCC. Cancer 1999;86:799–804. © 1999 American Cancer Society.

show abstract

Section: Discussionmentioning

confidence: 99%

Paraneoplastic syndromes in patients with hepatocellular carcinoma in Taiwan

Luo

Hwang

et al. 1999

Cancer

View full text Add to dashboard Cite

show abstract

“…Further, alpha-fetoprotein is shown in this study to be less sensitive and of inferior accuracy in the diagnosis of HCC when compared with DCP for patients presenting with tumour size ≥3 cm. The sensitivity of 62.8 % is lower than 83.7 % reported in 1988 in South Africa [ 13 ] 66 percent in 1974 in Uganda, [ 33 ] and 90 % in 1992 in Zaire [ 34 ]. This may partly be due to the fact that some of the studies were done using immuno - diffusion method rather than radioimmunoassay and enzyme immunoassay.…”

Section: Discussionmentioning

confidence: 67%

“…A correlation has been found to exist between HBsAg positivity and serum AFP levels in HCC patients. HCC patients who are positive for HBsAg are significantly more likely to be AFP positive and have higher levels of AFP than those who are not, suggesting a relationship between HBV infection and AFP production [ 27 , 33 , 40 ]. Similarly, DCP has also been reported to perform better in those with viral aetiology [ 31 ].…”

Section: Discussionmentioning

confidence: 99%

Utility of serum des-gamma-carboxyprothrombin in the diagnosis of hepatocellular carcinoma among Nigerians, a case–control study

et al. 2015

View full text Add to dashboard Cite

BackgroundHepatocellular Carcinoma (HCC) is a common malignancy occurring globally but with a dismal prognosis. Des-gamma-carboxyprothrombin (DCP) has been reported to be more sensitive and specific than Alpha-fetoprotein (AFP) in the diagnosis of HCC among the White population. Its efficacy among the Black population is yet to be established. The aim of this study therefore, was to determine the relative sensitivity and specificity of des-gamma-carboxyprothrombin and alpha-fetoprotein in the diagnosis of hepatocellular carcinoma in a cohort of Nigerian patients presenting at a single referral centre.MethodsCross-sectional case–control study was carried out using 62 HCC patients and 57 controls with benign liver diseases including chronic hepatitis and compensated liver cirrhosis. Both DCP and AFP were tested using enzyme immunoassay methods.ResultsSixty-nine percent of the HCC patients presented with tumour sizes >5 cm while 31 % presented with tumour sizes 3-5 cm. No patient presented with tumour sizes <3 cm. The sensitivity and specificity of DCP were 96.8 % and 98.3 % respectively, based on a Receiver operating characteristic (ROC) curve - derived optimum cut-off level of >140mAU/ml. Similarly, the sensitivity and specificity of AFP were 62.9 % and 93.3 % at an ROC - derived optimum cut-off level of 18mAU/ml. The area under the receiver operating characteristic curve (AUROC) for DCP was 0.99 and was significantly larger than that of AFP which was 0.85 (p < 0.001).ConclusionIn conclusion, the utility of DCP for the diagnosis of HCC among Nigerian patients was higher than that of AFP for large tumours with diameter ≥3 cm.

show abstract

“…Also, there appears to be no significant difference in survival between serum AFP-positive and negative patients. 29 Our tumors containing IHG have mostly been well to moderately differentiated; the five from patients with positive serum AFP were all moderately well-differentiated. T h e globules in liver cells of Pi-type ZZ alpha-1-antitrypsin deficient patients with concomitant primary liver cell carcinomas may render the hepatocytes susceptible to injury by additional factors ultimately resulting in hepatic fibrosis, cirrhosis, and malignant he pa to ma^.^^'^ Whether the IHG noted in the tumor cells of hepatocellular carcinomas are of importance in carcinogenesis and whether they will assist in the assessment of prognosis remains to be seen.…”

Section: Discussionmentioning

confidence: 84%

Intracytoplasmic hyaline globules in hepatocellular carcinomas

Cohen¹

1976

Cancer

View full text Add to dashboard Cite

Intracytoplasmic hyaline globules (IHG) were found in 16 out of 105 hepatocellular carcinomas (15.2%). In all cases, there was a male preponderance, most of the patients were Black, and the mean age was in the fifth decade. IHG were mostly noted in the better-differentiated tumors. Bile production was present in 12% of all tumors. Over 80% of tumors with globules showed necrosis as compared with 40% of the tumors without globules. Cirrhosis was present in almost half the cases, with liver cell dysplasia in 15%. These globules are possibly alpha-fetoprotein. Some of them may be giant lysosomes. Their role in carcinogenesis and prognosis is uncertain.

show abstract

Serum alpha-fetoprotein in 184 ugandan patients with hepatocellular carcinoma.Clinical, laboratory, and histopathologic correlations

Cited by 38 publications

References 20 publications

Paraneoplastic syndromes in patients with hepatocellular carcinoma in Taiwan

Paraneoplastic syndromes in patients with hepatocellular carcinoma in Taiwan

Utility of serum des-gamma-carboxyprothrombin in the diagnosis of hepatocellular carcinoma among Nigerians, a case–control study

Intracytoplasmic hyaline globules in hepatocellular carcinomas

Contact Info

Product

Resources

About